Europe
Inceptua and Bendalis enter into an exclusive oncology medicine supply agreement for clinical trials
The global pharmaceutical company and service partner Inceptua Group and Bendalis GmbH – German manufacturer of generic oncology drugs and special therapeutic agents, announce the signing of an exclusive clinical trial supply agreement for oncology generics.
Vaccitech progresses clinical development of Universal Influenza A Vaccine (VTP-100) in Belgium and Australia and expects top-line data in early 2020
Alzheimer’s Research UK welcomes the Conservatives’ pledge to double investment in dementia research as a ‘step in the right direction’.
Flamma SpA is proud to announce that Mr. Gian Paolo Negrisoli, Flamma CEO, has been granted Honorary Dalian Citizenship for his friendship to China and his contribution in promoting economic exchanges and cooperation through Flamma Honkai.
Promore Pharma AB has prepared a supplementary prospectus to the prospectus regarding the rights issue of approx.
Pembrolizumab either used alone or in combination with chemotherapy was more effective than a standard cocktail of chemotherapy drugs in a study involving nearly 900 patients.
Official inauguration ceremony of the new facility for the development and manufacturing of biopharmaceuticals
Effective treatments for diabetes are becoming more and necessary. The past few years have demonstrated productive strides in drug therapies, such as following medications.
Tecentriq is the company’s PD-L1 checkpoint inhibitor. Avastin is an antibody that binds to VEGF and interferes with tumor blood supply.
“We are excited about entering into an agreement to acquire The Medicines Company as inclisiran is a potentially transformational medicine that reimagines the treatment of atherosclerotic heart disease and familial hypercholesterolemia,” said Vas Narasimhan, chief executive officer of Novartis.
PRESS RELEASES